Lopinavir

Routes
Oral (PO)
Half-Life (t½)
PO: 6h
Formula
C37H48N4O5
Molecular Weight
628.8 g/mol
PubChem CID
92727
Aliases
ABT-378, LPV, Kaletra (with ritonavir)

Pharmacological Mechanism

HIV protease inhibitor — clinically available only as the Kaletra co-formulation with ritonavir (LPV/r 200/50 mg). Ritonavir component is sub-therapeutic for HIV but boosts lopinavir AUC ~80× via CYP3A4 inhibition. Largely displaced by integrase-inhibitor-based first-line regimens (DTG, BIC, RAL); retained for second-line use, pediatric HIV, and post-exposure prophylaxis in some settings. Investigated and rejected for COVID-19 (Recovery trial 2020 — no mortality benefit). Common AE: hyperlipidemia, insulin resistance, GI intolerance (worse than DRV/c). PK (Kaletra label, boosted 400/100 mg PO bid with RTV at SS): Cmax 9.8 ± 3.7 µg/mL, Cmin 5.5 ± 2.7 µg/mL, AUCtau (0-12) 92.6 ± 36.7 µg·h/mL. t½ ~6 h (boost makes effective t½ longer due to CYP3A4 inhibition). CL/F per 12-h interval ≈ 4.3 L/h, V/F ≈ 37 L.

Half-Life & Elimination Curve (PO: 6h)

100%50%25%12.5%0%0h0×t½6h1×t½12h2×t½18h3×t½24h4×t½30h5×t½0×t½ (0h): 100% remaining (~7.57 mg/L)1×t½ (6h): 50% remaining (~3.79 mg/L)2×t½ (12h): 25% remaining (~1.89 mg/L)3×t½ (18h): 12.5% remaining (~0.946 mg/L)4×t½ (24h): 6.3% remaining (~0.473 mg/L)5×t½ (30h): 3.1% remaining (~0.237 mg/L)
Plasma (PO)t½ Decay (6h)
  • 0×t½0h100% (7.57 mg/L)
  • 1×t½6h50% (3.79 mg/L)
  • 2×t½12h25% (1.89 mg/L)
  • 3×t½18h12.5% (0.946 mg/L)
  • 4×t½24h6.3% (0.473 mg/L)
  • 5×t½30h3.1% (0.237 mg/L)
Elimination t½6h (PO)
Rate Constant (ke)0.116 h⁻¹
Time to Peak (Tmax)3.08h
Est. Peak (Cmax)7.57 mg/L
Clearance (CL)4.27 L/h
97% Washout (5×t½)30h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References